August 2012
-
The FDA has granted Adapt Pharma Fast Track designation for its intranasal naloxone for the treatment of opioid overdose, the company said. Adapt Pharma licensed the product from Lightlake Therapeutics in December 2014. In the… Read more . . .
-
Lupin Limited and Polish biopharmaceutical company Celon Pharma have announced that they will co-develop a generic version of GSK’s Advair Diskus. Celon, which currently markets a fluticasone/salmeterol DPI called Salmex in Poland, will supply the… Read more . . .
-
Actavis has announced that after the United States District Court for the District of New Jersey denied AstraZeneca’s request for a permanent injunction and ruled that US Patent No. 7,524,834 is invalid, Actavis launched its… Read more . . .
-
Since 2000, developers of immediate-release oral drugs have been able to request waivers of in vivo bioequivalence studies based on the FDA’s Biopharmaceutics Classification System (BCS). Now a workshop sponsored by the AAPS Inhalation and… Read more . . .
-
GSK has relied heavily on social media to get out the word that its Flonase fluticasone propionate nasal spray is now available over the counter in the United States. The FDA approved Flonase OTC in… Read more . . .
-
PARI has announced that it has begun supplying nebulizer compressors to patients using its new Kitabis Pak through a program called PARI Provide. Kitabis Pak, which includes generic tobramycin inhalation solution packaged with a PARI… Read more . . .
-
Dance Biopharm has announced the appointment of former Dynavax chief medical officer and president J. Tyler Martin as President, a newly created position. Martin has also been appointed a member of the board of directors.… Read more . . .
-
Hosokawa Micron has introduced the Mini Cyclomix lab mixer for use in development of dry powder formulations for inhalation, the company announced. According to the company, the lab-sized blender is designed to disperse API in… Read more . . .
-
Theravance has announced that the the FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) and Drug Safety and Risk Management Advisory Committee will meet jointly on March 19, 2015 to discuss whether the Breo Ellipta fluticasone/vilanterol DPI… Read more . . .
-
GlaxoSmithKline and Theravance have announced the beginning of the FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy) Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI in patients with… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland